ATXN1L Loss

CI-VAR-00002485Explore in graph →CIViC 1879

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Pancreatic Neoplasm1
ATXN1L Loss	Trametinib	Predictive	D	Supports Resistance	3	submitted	EID5123 ATXN1L loss reduced sensitivity to trametinib in KRAS G12V pancreatic cancer cells (PATU8902, PATU8988T). PMID 28178529 · Wang et al., 2017 · Open in CIViC	civic
Melanoma1
ATXN1L Loss	Dabrafenib + VemurafenibSubstitutes	Predictive	B	Supports Resistance	3	submitted	EID5124 ATXN1L expression was analyzed in 30 BRAF V600-mutant untreated melanoma metastes. 21 of these patients were subsequently treated with dabrafenib or vemurafenib, and 9 of these patients were treated w… (full text at CIViC) PMID 28178529 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.